Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

Global revenues of Copaxone® (20 mg/mL and 40 mg/mL), the leading multiple sclerosis therapy in the U.S. and globally, amounted to $1.0 billion, an increase of 9% compared to the first quarter of 2015.

Copaxone® revenues in the United States amounted to $821 million, an increase of 12% compared to the first quarter of 2015. The increase was mainly due to higher net pricing, including a price increase of 7.9% in January 2016.

At the end of the first quarter of 2016, according to March 2016 IMS data, our U.S. market shares for the Copaxone® products in terms of new and total prescriptions were 28.1% and 29.8%, respectively.

Copaxone® 40 mg/mL accounted for over 81% of total Copaxone® prescriptions in the U.S.

Glatopa hasn't slowed the 40mg rollout whatsoever.